Alaunos acquires Velaris Therapeutics alongside $350 million financing for pulmonary hypertension pipeline
Alaunos Therapeutics has acquired Velaris Therapeutics in a stock-for-stock transaction supported by a separate $350 million financing to advance pulmonary hypertension treatments.
The acquisition brings Velaris' investigational pulmonary arterial hypertension and cardiopulmonary programmes into Alaunos, with a private placement led by Fairmount and other investors providing development capital.
The financing is distinct from the acquisition consideration and is expected to support the combined company's pipeline, with a projected cash runway extending into 2029.
Field | Content |
Article Type | Deals |
Companies | Alaunos Therapeutics; Velaris Therapeutics |
Deal Type | Acquisition and concurrent private placement |
Acquirer | Alaunos Therapeutics |
Target | Velaris Therapeutics |
Acquisition Consideration | Stock-for-stock transaction; valuation not specified in supplied summary |
Concurrent Financing | $350 million private placement |
Financing Participants | Fairmount and other investors |
Transaction Status | Acquisition completed and announced |
Acquisition Date | 13 October 2026 |
Therapeutic Areas | Pulmonary arterial hypertension and related cardiopulmonary conditions |
Development Stage | Investigational therapeutic pipeline |
Pipeline Origin | Velaris Therapeutics; associated with Paragon |
Projected Cash Runway | Into 2029 |
Geography | United States |
What Happened | Alaunos acquired Velaris Therapeutics through a stock-for-stock transaction accompanied by a separate $350 million private placement. |
Why It Matters | The transaction repositions Alaunos around pulmonary hypertension development and provides substantial financing to support its investigational pipeline. |
Strategic Rationale | The acquisition adds Velaris' cardiopulmonary programmes while the financing supports continued research and clinical development. |
Key Takeaway | Alaunos has acquired Velaris and secured $350 million in financing; the financing amount should not be presented as the acquisition purchase price. |
What to Watch | Lead programme development, clinical trial timelines, financing deployment and updated corporate pipeline guidance. |
Primary Source | Alaunos Therapeutics investor announcement |
Relevant Date | 13 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言